摘要
背景:巨噬细胞移动抑制因子(MIF)在20世纪60年代首次被描述为影响多种免疫细胞的多效性细胞因子。 已经报道了主要涉及诸如趋化因子样功能和调节全身应激反应的炎症反应的不同生理功能。 目的:在一些临床研究中,使用MIF作为生物标志物已被研究用于炎症方面的疾病如脓毒症,全身感染和自身免疫性疾病的有前景的支持。 本文详细回顾了临床数据并评估了作为关注炎症和自身免疫疾病的生物标志物的功能。 结论:最近的研究表明MIF是不同炎性疾病的标志物,并可能成为未来的治疗靶点。
关键词: MIF,生物标志物,感染性疾病,自身免疫性疾病,细胞因子,CD74,CXCR。
Current Medicinal Chemistry
Title:Macrophage Migration Inhibitory Factor - A Favorable Marker in Inflammatory Diseases?
Volume: 25 Issue: 5
关键词: MIF,生物标志物,感染性疾病,自身免疫性疾病,细胞因子,CD74,CXCR。
摘要: Background: Macrophage migration inhibitory factor (MIF) was firstly described in the 1960s as a pleiotropic cytokine affecting a variety of immune cells. Different physiological functions mainly involving inflammatory reactions such as chemokine-like function and regulating systemic stress responses have been reported.
Objective: In several clinical studies the use of MIF as a biomarker has been investigated promising support for diseases with an inflammatory aspect such as sepsis, systemic infections and autoimmune diseases. This article in detail reviews clinical data and evaluates the function as biomarker focusing on inflammatory and autoimmune diseases.
Conclusion: Recent studies suggest MIF to be a marker for different inflammatory diseases and might serve as therapeutic target in the future.
Export Options
About this article
Cite this article as:
Macrophage Migration Inhibitory Factor - A Favorable Marker in Inflammatory Diseases?, Current Medicinal Chemistry 2018; 25 (5) . https://dx.doi.org/10.2174/0929867324666170714114200
DOI https://dx.doi.org/10.2174/0929867324666170714114200 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Type I Interferon as a Target of Treatment in SLE
Endocrine, Metabolic & Immune Disorders - Drug Targets Analogs of the Sea Anemone Potassium Channel Blocker ShK for the Treatment of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy
Current Pharmaceutical Design Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Colon as Target for Drug Delivery
Current Drug Therapy Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry Emerging Treatment Strategies and Potential Therapeutic Targets in Primary Sjogrens Syndrome
Inflammation & Allergy - Drug Targets (Discontinued) Restoration of the Immune Balance by Autologous Bone Marrow Transplantation in Juvenile Idiopathic Arthritis
Current Stem Cell Research & Therapy Dietary N-3 Fatty Acids and Calorie Restriction in Autoimmune Disease:Influence in Different Immune Compartments
Current Organic Chemistry The Impact of Post-Genomics Approaches in Neurodegenerative Demyelinating Diseases: The Case of Guillain-Barré Syndrome
Current Medicinal Chemistry Bioinformatic Screening of Autoimmune Disease Genes and Protein Structure Prediction with FAMS for Drug Discovery
Protein & Peptide Letters Associations between Depressive Disorders and Inflammatory Rheumatic Diseases
Current Topics in Medicinal Chemistry Clinical Queries Addressed in Patients with Systemic Autoimmune Diseases. Can Cardiovascular Magnetic Resonance Give the Final Solution?
Inflammation & Allergy - Drug Targets (Discontinued) Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology Identification of Moesin as a Novel Autoantigen in Patients with Sjögren’s Syndrome
Protein & Peptide Letters The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Targeted Therapies – Many Ways to (the Peace of) Rome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Desirability Based Optimization of New Mesalazine Modified Release Formulations: Compression Coated Tablets and Mini Tablets in Capsules
Letters in Drug Design & Discovery Endothelial Chemokines in Autoimmune Disease
Current Pharmaceutical Design